Pan Canadian Pharmaceutical Alliance

pan-Canadian Pharmaceutical Alliance (pCPA): July 2021 Trends and Insights   July 2021 Highlights: 5 products completed CADTH review 5 products initiated pCPA negotiations 3 negotiations were completed with an LOI 1 negotiation was closed without an LOI 1 file was closed without negotiation   Key Take-Aways: CADTH released no non-oncology recommendations in July. The volume of files under consideration remains relatively stable in July at 30, with no decrease in…

pan-Canadian Pharmaceutical Alliance (pCPA): June 2021 Trends and Insights   June 2021 Highlights: 8 products completed CADTH review 12 products initiated pCPA negotiations 3 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation   Key Take-Aways: The volume of files under consideration remains stable with a slight decrease in the days under consideration in June relative to the last 6…

pan-Canadian Pharmaceutical Alliance (pCPA): May 2021 Trends and Insights   May 2021 Highlights: 6 products completed CADTH review 3 products initiated pCPA negotiations 3 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 files were closed without negotiation   Key Take-Aways: May sees continued consistency in both the volume of files under consideration and the average days under consideration which is hovering around the 5-month…

pan-Canadian Pharmaceutical Alliance (pCPA): April 2021 Trends and Insights   April 2021 Highlights: 5 products completed CADTH review 6 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 file was closed without negotiation   Key Take-Aways: The volume of files under consideration has remained relatively high and stable for the last 5 months (27-30), although the ratio of oncology to…

pan-Canadian Pharmaceutical Alliance (pCPA): March 2021 Trends and Insights   March 2021 Highlights: 5 products completed CADTH review 3 products initiated pCPA negotiations 2 negotiations were completed with an LOI 3 negotiations were closed without an LOI 0 files were closed without negotiation   Key Take-Aways: The average duration that files are under consideration reaches an annual peak of ~160 days. In addition, the number of files under consideration matches…

pan-Canadian Pharmaceutical Alliance (pCPA): February 2021 Trends and Insights   February 2021 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 6 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation   Files Under pCPA Consideration: CADTH issued 5 new recommendations in February (28 files under pCPA consideration as of Feb 28) – down from 29 in January.…

pan-Canadian Pharmaceutical Alliance (pCPA): January 2021 Trends and Insights   January 2021 Highlights: 4 products completed CADTH review 9 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in January (29 files under pCPA consideration as of January 31) – down from…

pan-Canadian Pharmaceutical Alliance (pCPA): December 2020 Trends and Insights   December 2020 Highlights: 8 products completed CADTH review 2 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 files were closed without negotiation Beginning this month and over the next few months, the pCPA is introducing a Targeted Negotiation Process (TNP) to address selected files that have been on hold…

pan-Canadian Pharmaceutical Alliance (pCPA): November 2020 Trends and Insights   November 2020 Highlights: 4 products completed CADTH review 8 products initiated pCPA negotiation 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in November (24 files under pCPA consideration as of November 30) – down…

pan-Canadian Pharmaceutical Alliance (pCPA): October 2020 Trends and Insights   October 2020 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 5 new recommendations in October (22 files as of October 31). PRODUCT INDICATION SPONSOR Type REC’N* DATE Xtandi** (enzalutamide) Metastatic…

pan-Canadian Pharmaceutical Alliance (pCPA): September 2020 Trends and Insights   September 2020 Highlights: 1 product completed CADTH review 0 products initiated pCPA negotiations 2 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation   Files Under pCPA Consideration: CADTH issued 1 new recommendation in September (25 files as of September 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Zejula (niraparib) Ovarian…

pan-Canadian Pharmaceutical Alliance (pCPA): August 2020 Trends and Insights   August 2020 Highlights: 2 products completed CADTH review 2 products initiated pCPA negotiations 1 negotiation was completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 2 new recommendations in August (25 files as of August 31). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Soliris (eculizumab) Neuromyelitis…

pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights   July 2020 Highlights: 6 products completed CADTH review 6 products initiated pCPA negotiations 7 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, negotiations are taking longer to start…

pan-Canadian Pharmaceutical Alliance (pCPA): June 2020 Trends and Insights   June Highlights: 4 products completed CADTH review 7 products initiated pCPA negotiations 4 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 4 new recommendations in June (23 files as of June 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Cuvposa (glycopyrrolate) Chronic severe…